New combo therapy may help preserve insulin-making cells in type 1 diabetes

NCT ID NCT05742243

First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This study tested whether combining two immune therapies—abatacept (injected weekly) and nasal insulin (sprayed into the nose)—can help preserve the pancreas's ability to make insulin in people recently diagnosed with type 1 diabetes. 68 participants aged 6 to 21 took part for 48 weeks of treatment plus 48 weeks of follow-up. The goal is to make blood sugar control easier and reduce the need for injected insulin.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Perth Children's Hospital

    Nedlands, Western Australia, 6009, Australia

  • Queensland Children's Hospital

    South Brisbane, Queensland, 4101, Australia

  • The Children's Hospital at Westmead

    Westmead, New South Wales, 2145, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, 3052, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, 3050, Australia

  • Women's and Children's Hospital

    North Adelaide, South Australia, 5006, Australia

Conditions

Explore the condition pages connected to this study.